Summary & Overview
HCPCS Level II M0234: Tocilizumab-aazg IV Infusion, Second Dose
HCPCS Level II code M0234 denotes a second intravenous infusion of tocilizumab-aazg for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. The code bundles the infusion procedure and immediate post-administration monitoring. This designation matters nationally because it aligns a specific biologic therapy and administration episode with a standardized billing pathway during acute inpatient COVID-19 care, aiding hospitals and payers in categorizing high-cost, acute-phase therapeutic interventions.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what this code represents clinically and operationally, how it applies in the hospital inpatient setting, and which major payers are typically relevant for coverage and claims processing. The publication provides benchmarks and policy context where available, summarizes payer coverage patterns and prior authorization trends, and outlines clinical scenarios that match the code's description (second-dose tocilizumab infusion for corticosteroid-treated, oxygen-dependent hospitalized adults). Any missing input elements are identified as not available in the input.
Billing Code Overview
HCPCS Level II code M0234 describes an intravenous infusion of tocilizumab-aazg given as a second dose for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The description includes the infusion and post-administration monitoring.
Service Type: Intravenous infusion, inpatient acute care medication administration and monitoring
Typical Site of Service: Hospital inpatient setting (acute care), including intensive care units
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult with severe COVID-19 pneumonia receiving systemic corticosteroids and requiring supplemental oxygen or ventilatory support is evaluated for adjunctive immunomodulatory therapy. The patient has hypoxemia on supplemental oxygen via nasal cannula or high-flow device, or is receiving non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). After infectious disease and critical care teams confirm indications and review contraindications (active uncontrolled infection, elevated transaminases beyond recommended thresholds, or severe neutropenia/thrombocytopenia), an order for intravenous tocilizumab is placed for a single dose with the potential for a second dose per institutional protocol. The clinical workflow includes: medication order entry and allergy verification; baseline labs (CBC, CMP, liver enzymes, coagulation studies); pharmacy preparation and verification of tocilizumab-aazg dose; infusion in an inpatient infusion suite, ICU, or step-down unit with continuous monitoring (vital signs, oxygenation) during infusion; documentation of infusion start and stop times, lot number, and administration site; post-administration monitoring for infusion reactions and delayed adverse events; and reassessment for clinical response and need for a second dose. Billing captures the infused biologic, administration, and post-administration monitoring under the HCPCS Level II code M0234 representing the second dose of intravenous tocilizumab-aazg for hospitalized adult COVID-19 patients meeting the specified clinical criteria.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|